VivoSense Closes $25M Series A Funding
Summary
VivoSense, Inc., a Newport Beach, Calif.-based agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, closed a $25M Series A financing round. Led by Dudley Tabakin, chief executive officer, VivoSense is innovating within the pharmaceutical clinical trial industry by developing new digital biomarkers using their expansive toolkit of proprietary software. The platform is designed to deliver real-world digital clinical measures from wearable sensors, which will help to advance patient-focused drug development and precision medicine for patients with cancer, Alzheimer’s, rare disease and other therapeutic indications. The technology allows interpretation of subtle shifts in human physiology through customized, body-worn monitoring and analysis solutions rooted in scientific foundations. Following the deal, the VivoSense board of directors will consist of current members and co-founders Dudley Tabakin and Lance Myers, as well as new additions, Chris Garabedian and Tanja Dowe.
Funding
Review available funding amount, funding date, investors, and linked company information related to VivoSense Closes $25M Series A Funding in the interactive ISVWorld profile.